Display options
Cite
Valenti L, Pelusi S, Cherubini A, et al. Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion. 2021;61(12):3381-3389doi: 10.1111/trf.16693.
Valenti, L., Pelusi, S., Cherubini, A., Bianco, C., Ronzoni, L., Uceda Renteria, S., Coluccio, E., Berzuini, A., Lombardi, A., Terranova, L., Malvestiti, F., Lamorte, G., Erba, E., Oggioni, M., Ceriotti, F., & Prati, D. (2021). Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion, 61(12), 3381-3389. https://doi.org/10.1111/trf.16693
Valenti, Luca, et al. "Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors." Transfusion vol. 61,12 (2021): 3381-3389. doi: https://doi.org/10.1111/trf.16693
Valenti L, Pelusi S, Cherubini A, Bianco C, Ronzoni L, Uceda Renteria S, Coluccio E, Berzuini A, Lombardi A, Terranova L, Malvestiti F, Lamorte G, Erba E, Oggioni M, Ceriotti F, Prati D. Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion. 2021 Dec;61(12):3381-3389. doi: 10.1111/trf.16693. Epub 2021 Oct 14. PMID: 34647620; PMCID: PMC8661834.
Copy Download .nbib Format: NLM
Share it on

Transfusion. 2021 Dec;61(12):3381-3389. doi: 10.1111/trf.16693. Epub 2021 Oct 14.

Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors.

Transfusion

Luca Valenti, Serena Pelusi, Alessandro Cherubini, Cristiana Bianco, Luisa Ronzoni, Sara Uceda Renteria, Elena Coluccio, Alessandra Berzuini, Angela Lombardi, Leonardo Terranova, Francesco Malvestiti, Giuseppe Lamorte, Elisa Erba, Massimo Oggioni, Ferruccio Ceriotti, Daniele Prati

Affiliations

  1. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
  2. Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milano, Italy.
  3. Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milano, Italy.
  4. Respiratory Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milano, Italy.

PMID: 34647620 PMCID: PMC8661834 DOI: 10.1111/trf.16693

Abstract

BACKGROUND: A large proportion of SARS-CoV-2-infected individuals does not develop severe symptoms. Serological tests help in evaluating the spread of infection and disease immunization. The aim of this study was to prospectively examine the trends and risk factors of SARS-CoV-2 infection in blood donors.

STUDY DESIGN AND METHODS: We screened 8798 asymptomatic donors presenting in Milan from July 2020 to February 2021 (10,680 presentations) before the vaccination campaign for anti-nucleoprotein (NP) antibodies, and for anti-spike receptor-binding domain (RBD) antibodies and nasopharyngeal swab PCR in those who tested positive.

RESULTS: The prevalence of anti-NP+/RBD+ tests increased progressively with time up to ~15% (p < .0001), preceded by a peak of PCR+ tests. Anti-RBD titers were higher in anti-NP IgG+/IgM+ than in IgG+/IgM- individuals and in those with a history of infection (p < .0001); of these 197/630 (31.2%) displayed high titers (>80 AU/ml). Anti-RBD titers declined during follow-up, depending on baseline titers (p < .0001) and time (p = .025). Risk factors for seroconversion were a later presentation date and non-O ABO blood group (p < .001). A positive PCR was detected in 0.7% of participants in the absence of SARS-CoV-2 viremia.

CONCLUSIONS: During the second wave of SARS-CoV-2 infection in Northern Italy, we detected an increase in seroprevalence in healthy blood donors from ~4% to ~15%, with a trend paralleling that observed in the general population. Seroconversion was more frequent in carriers of non-O blood groups. The persistence of anti-RBD antibodies was short-lived.

© 2021 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.

Keywords: ABO blood group; COVID-19; anemia; epidemiology; ferritin

References

  1. J Clin Med. 2020 Oct 01;9(10): - PubMed
  2. N Engl J Med. 2020 Oct 15;383(16):1522-1534 - PubMed
  3. Blood. 2021 Mar 25;137(12):1573-1581 - PubMed
  4. Blood Transfus. 2021 May;19(3):181-189 - PubMed
  5. Nature. 2021 Jul 8;: - PubMed
  6. Transfusion. 2020 Dec;60(12):3067-3070 - PubMed
  7. Lancet Infect Dis. 2020 May;20(5):533-534 - PubMed
  8. JAMA. 2021 Oct 12;326(14):1400-1409 - PubMed
  9. Transfusion. 2021 Dec;61(12):3381-3389 - PubMed
  10. Clin Microbiol Infect. 2021 Apr;27(4):511-519 - PubMed
  11. J Clin Microbiol. 2020 Aug 24;58(9): - PubMed
  12. Int J Infect Dis. 2021 Mar;104:458-464 - PubMed
  13. Vox Sang. 2021 Sep;116(8):849-861 - PubMed
  14. Nature. 2020 Aug;584(7821):425-429 - PubMed
  15. Acta Haematol. 2021;144(5):580-584 - PubMed
  16. JAMA. 2020 Apr 28;323(16):1574-1581 - PubMed
  17. N Engl J Med. 2020 Feb 20;382(8):727-733 - PubMed
  18. Lancet Haematol. 2020 Oct;7(10):e756-e764 - PubMed
  19. PLoS Med. 2020 Sep 22;17(9):e1003346 - PubMed
  20. J Med Virol. 2021 Apr;93(4):2160-2167 - PubMed
  21. Blood Transfus. 2021 Jul;19(4):277-280 - PubMed

Publication Types

Grant support